ACCESS Newswire·Nov 9, 2026, 8:30 AM ET

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics presented new preclinical data on November 7, 2026, at the Society for Immunotherapy of Cancer 2026 Annual Meeting regarding its next-generation multispecific platform.
Preclinical studies showed that molecules APVO451 & APVO452 activated immune cells to kill cancer cells even under conditions that normally suppress immune activity.
Preclinical findings for APVO711 demonstrated the ability to both activate immune cells & block a signal that weakens immune responses, offering a two-pronged approach against solid tumors.
The molecules are designed to overcome solid tumor defenses by combining CD40 activation with T-cell engagement or PD-L1 checkpoint blockade within a single therapeutic.
Aptevo's approach aims to concentrate immune activation within the tumor microenvironment to improve efficacy while reducing the risk of systemic side effects.
The company plans to advance APVO451 & other solid tumor candidates into investigational new drug-enabling studies in 2027.
Aptevo is also collaborating with Niowave to develop up to three radiopharmaceutical oncology programs, with the first expected to target nectin-4.
The company's pipeline includes eight candidates created using its proprietary ADAPTIR & ADAPTIR-FLEX platforms.
Aptevo's lead clinical candidate, mipletamig, is currently being evaluated in the RAINIER trial for acute myeloid leukemia & has received orphan drug designation.